A multistudy analysis of cediranib, a potent, selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), was conducted to establish population exposure-safety models for the relationship of cediranib exposure to the safety endpoints, diastolic and systolic blood pressure (DBP and SBP) and diarrhoea in cancer patients. These models were applied to predict safety outcomes for different cediranib dose regimens.
Introduction
Ovarian cancer is a leading cause of death from gynaecological cancers in the EU and USA. The current standard of care for treating platinum-sensitive relapsed (PSR) ovarian cancer is platinum-based doublet chemotherapy. Recently, angiogenesis has been validated as a therapeutic target in advanced ovarian cancer patients through the use of the monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab [1] . However, although bevacizumab has shown activity when combined with chemotherapy, the current indication does not support its use in those who have previously received this agent, or another VEGF inhibitor, in the first-line setting. Moreover, an increase in use of alternative VEGF ligands has been reported in patients with disease progressing on chemotherapy plus bevacizumab, suggesting that more comprehensive inhibition of VEGF signalling may be appropriate [2] . Therefore, a need remains for effective treatment options with an alternative anti-angiogenic treatment for patients at their first platinum-sensitive relapse.
Cediranib is a potent, small-molecule tyrosine kinase inhibitor of VEGF signalling and angiogenesis that targets all three VEGF tyrosine kinase receptors (VEGFR-1, -2 and -3) and has additional activity against stem cell factor receptor (ckit)-dependent tumour growth [3] [4] [5] [6] [7] [8] [9] . Cediranib, given as 20 mg or 30 mg once daily (qd) orally, is expected, at chronic oral dosing, to inhibit VEGF-driven angiogenesis and, therefore, constrain tumour growth. Cediranib in combination with olaparib is currently undergoing Phase III clinical trials in patients with ovarian cancer (NCT02446600 and NCT02502266).
Previously, a population pharmacokinetic model was developed for cediranib, with data collected from 19 Phase I or II studies in patients with varied types of cancer, to describe the cediranib concentration-time curve and evaluate the impact of patient covariates on cediranib pharmacokinetics [10] . The current analysis was conducted to establish models for the relationship of cediranib exposure to the safety endpoints, diastolic and systolic blood pressure (DBP and SBP) and diarrhoea, and to apply these models to predict safety outcomes for different cediranib dose regimens.
Methods

Data
Clinical study and measurement of hypertension and diarrhoea. Cediranib concentrations (precision [%CV] for the assay was <15%, with a lower limit of quantification [LLOQ] of 0.5 ng ml À1 and a linear range of up to 50 ng ml À1 ) and other relevant data from 19 Phase I and II studies with doses ranging from 0.5 to 90 mg (majority 20, 30 and 45 mg) were first used for a population pharmacokinetic analysis [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Of 19 studies, 10 Phase I and three Phase II studies with cediranib monotherapy were selected for this exposureresponse (E-R) analysis for DBP/SBP and diarrhoea events. All trials were approved by the respective independent ethics committees and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . The summary of the source trials and schedule of collections of cediranib concentrations and DBP/SBP events are shown in Table S1 . DBP/SBP was typically measured around maximum concentrations of cediranib predose and 1, 2, 3, 4, 6 and 8 h postadministration on the day of single dosing, or at steady state after once-daily repeated-dose administration. DBP/SBP data within 6 weeks of treatment, including only the first hypertensive intervention, were used for the analysis. Long-term data were excluded because of the complex nature of blood pressure intervention after longterm cediranib treatment. Diarrhoea events were reported daily by patients, with grades of mild, moderate and severe, during cediranib treatment. DBP/SBP and daily diarrhoea event data collected over the time of cediranib treatment were treated as repeated observations in the analysis.
Missing data and imputations. No imputations of missing DBP/SBP were performed. Diarrhoea data were imputed as daily observations with last observation carried forward or next observation carried backward.
Covariate data. When significant E-R for DBP/SBP or diarrhoea was identified, the covariates gender, age, and body weight were examined for potential impact on the E-R model. In addition, history of antihypertension medication was evaluated for DBP/SBP E-R.
Model development
Model development started from the base E-R model, followed by screening for covariate effects on relevant model parameters. A base E-R model was developed that included random effects, inter-individual variability (IIV), and residual error based on exploratory analysis of the data and potential mechanisms of cediranib-driven safety responses. This model was used as the basis for the covariate search, with a stepwise forward selection and backward deletion step as nested models.
E-R model development for DBP/SBP
Base model for DBP/SBP. The base model for DBP and SBP was simultaneously developed by considering the correlation between measurements of DBP and SBP within an individual starting from baseline models with data before the first dose and placebo only. Mean constant baseline models (Eq. (1)) for DBP and SBP were examined first:
where BP is the observed DBP/SBP at baseline or pre-dose without cediranib treatment, θ is the population (mean) DBP/SBP, and ε is the residual error parameter, which describes the deviation of the model-predicted baseline DBP/SBP from observed values: ε~N(0, σ 2 ), where σ 2 is the variance of ε. Subsequently, a baseline model with diurnal change in mean DBP/SBP with different periods, amplitudes, and phase shifts (Eq. (2)) was examined:
where BP, θ and ε are as defined above, N is the number of diurnal (cosine) functions to describe the diurnal change in baseline DBP/SBP, and A k , B k and ω k are the amplitude, phase shift and period of the kth diurnal function for baseline DBP/SBP, respectively. When an adequate baseline model was found, the diurnal model was fixed for the subsequent development of the drug effect model. 
where BP Drug represents the net impact of cediranib concentration on DBP/SBP, k in and k out are the input and elapse constants of producing BP in the absence of cediranib dose administration, and DEF is the drug effect on k in . BP is assumed to be stationary with a known initial value of BP 0 = k in /k out in the absence of cediranib. Consequently, only one of k in and k out needed to be estimated, and k out was set to be estimated in this analysis. Models for DEF that included linear (DEF = 1 + θ • C p ) and nonlinear impact of cediranib concentrations on k in were also evaluated as follows:
where C p is the predicted cediranib plasma concentration, E max is the maximum stimulating effect of cediranib concentration on k in , and EC 50 is the cediranib concentration required to produce half of the E max effect on k in .
Impact of antihypertensive change on DBP/SBP. Some patients changed antihypertensive treatment during the study. The DBP/SBP for these patients was modelled by:
where BP Change represents the scale change in DBP/SBP, θ 1 is the immediate change in DBP/SBP after a change in antihypertensive treatment, and θ 2 is the rate constant for dissipating the effect of change in antihypertensive drugs. Drug effect on BP (Eq. (3)) and change in antihypertensive treatment (Eq. (4)) were superimposed on the baseline DBP/SBP time course (Eq. (1) and Eq. (2)) to model DBP/SBP for the pooled drug-free and drug-on DBP/SBP data. All fixed-effect model parameters (θ in Eq. (1), θ, A k , B k and ω k in Eq. (2), k in , k out , E max and EC 50 in Eq. (3)/Eq. (4), and θ 1 and θ 2 in Eq. (5)) were evaluated for DBP and SBP, with a scale parameter for SBP relative to DBP for each of them if supported by data. Fixed-effect parameters were also evaluated for potential IIV. Correlation between IIVs for similar fixedeffect parameters to DBP and SBP was also modelled a priori in some cases because of the physiologically based correlation between DBP and SBP. In addition, since DBP and SBP were measured in pairs, inter-measurement correlation between DBP and SBP within an individual was also assumed through the L2 functionality in NONMEM.
Covariate model for DBP/SBP E-R model. The effect of the covariates gender, age and body weight on the DBP/SBP E-R model was evaluated for the drug-related model parameters E max and EC 50 in Eq. (4) .
The relationship between the continuous covariates age and weight and the typical E-R model parameters (θ TV ) was described using power models (Eq. (6)): 
where θ REF is the typical cediranib pharmacodynamic parameter at the reference value (one of categorical covariates) of X i , and θ x is the proportional change in θ REF for a particular category of X i other than the reference category. X i is the indicator variable for a category of categorical covariates, with 1 being in the category and 0 otherwise.
E-R model for diarrhoea events
Diarrhoea data were labelled as numeric scores in the dataset (0 = none, 1 = mild, 2 = moderate, 3 = severe) and modelled as ordered categorical variables using logistic regression analysis. A similar approach for other self-reported side effects has been published by Zingmark et al. [27] .
Base model for E-R modelling of diarrhoea events. The probability of a diarrhoea event with a grade of none, mild, moderate or severe for patient i at sampling time j, p ij , was modelled by:
and formulated as the log of the odds ratio:
The logit, λ ij , was modelled as a function of independent variables, including population mean constant and individual random effect parameters (η i ), to account for the difference in observed and predicted probability of the event as the base model (Eqs. (10)- (12)):
where λ ij,DS ≥ 1, λ ij,DS ≥ 2 and λ ij,DS ≥ 3 denote the logit of the probability of having a diarrhoea score (DS) of ≥1, ≥2 and ≥3, respectively, at baseline. B1, B2 and B3 are model parameters, with B2 and B3 constrained to be negative to meet the criterion P(DS≥3) ≤ P(DS≥2) ≤ P(DS≥1).
Drug effect and covariate model for E-R modelling of diarrhoea events. Drug effect (DEF) and/or covariate effect (CEF) on the probability of diarrhoea scores were modelled as additive to the baseline logit as follows:
Average cediranib concentrations (C av ) were used to model the drug effect on the logit, with the linear model (DEF = θ • C av ) and E max model (DEF = E max • C av /(EC 50 + C av ) being primarily evaluated.
To account for the serial correlation of diarrhoea events, a Markov parameter (m) was added to the logit models (Eqs (13)- (15)). For example, for a grade 1 diarrhoea event, the logit model Eq. (13) was modified as:
Simulation. The final E-R models for DBP/SBP and diarrhoea were used to visualize the DBP/SBP and diarrhoea response to a wide range of cediranib exposures. The typical average effect within a dosing interval at steady state was simulated using the obtained exposure-effect relationships. To visualize uncertainty in the estimated relationships, 1000 samples were drawn from the variance-covariance matrices of each corresponding model to create 95% confidence intervals (CIs) for the typical effect.
Software. distributed with q degrees of freedom (where q is the number of additional parameters in the more complex model), and a test model will be considered a statistically significant improvement if ÀΔOFV > χ 2 0:99 q ð Þ . For covariate modelling, P < 0.01 and P < 0.001 were used as the levels of significance for the forward inclusion and backward elimination of covariates, respectively. In addition, reductions in IIV and/or residual variability were also considered.
Model evaluation. Model evaluation included standard diagnostic plots, such as observed data vs. population predictions (PRED) and individual predictions (IPRED) and conditional weighted residual error vs. PRED and vs. time. In addition, VPC was used to evaluate model fit. In the case of logistic regression models for diarrhoea, this was the main mode of model diagnostic. VPC was constructed by repeatedly incorporating random draws from the model random-effect distributions, together with the fixed effects, to generate a population of predicted drug concentrations as functions of dose, time and patient characteristics. Plots of the observed data distributions were compared with the simulated distributions to demonstrate the model's ability to adequately describe the data. In order to account for different dose administrations, prediction-corrected VPCs were performed [30] . VPC was also stratified on the different covariates to evaluate the covariate effects identified. Substantial overlap of simulated and observed quantiles of cediranib concentrations would qualify the population pharmacokinetic model as suitable for simulation studies. The final model was determined on the basis of maximized likelihood (lowest objective function value [OFV]), physiological plausibility of parameter values, successful numeric convergence, acceptable VPC, and standard error of model parameter being no greater than 50%.
Results
Data
DBP/SBP and diarrhoea data from 631 patients in 10 Phase I and three Phase II studies of cediranib monotherapy were pooled for this analysis. Of those patients, 360 (57%) were male, 252 (40%) had previously taken antihypertensive drugs, and a majority (542; 85%) were Caucasian. The mean age was 58 years (range 19-89), while mean body weight was 75 kg (range 35-139).
A majority of patients (333; 52.7%) received a starting cediranib dose of 45 mg, while 168 (26.6%) and 87 (13.8%) received starting doses of 30 and 20 mg, respectively. Together, the 0.5, 1, 2.5, 5, 10 and 60 mg dose groups comprised only 43 patients (6.8%). Approximately 15 000 pairs of DBP/SBP measurements and 110 000 daily observations or imputations of diarrhoea grade were pooled for this analysis.
Exposure-response model for hypertension (DBP/SBP)
Base model. DBP and SBP were modelled simultaneously by considering their inter-measurement correlation within an individual. This yielded three separate residual errors: one common additive error model shared by both DBP and SBP, one separate additive error model for DBP, and a separate proportional error model for SBP. The final baseline model comprised a circadian rhythm model accounting for time of DBP/SBP measurement and two cosine functions with periods of 24 h and 12 h. The amplitude of the diurnal rhythm was found to vary between individuals and the magnitude of intra-day variation differed between DBP and SBP, with SBP varying more than DBP.
Drug effect model. The base model for DBP/SBP was developed using drug-free (pre-dose) data and was fixed for the development of the E-R model. The final E-R model included an indirect response relationship driven by cediranib plasma concentrations; the effect of cediranib concentrations on DBP/SBP was modelled as a maximum effect (E max ) model proportional to the baseline DBP/SBP model. Effect delay and E max were estimated to be different between DBP and SBP. IIV for E max was also estimated.
Model for change in antihypertensive drug. The antihypertension intervention effect, defined as change in or addition to existing antihypertension treatment, was modelled as an immediate constant change in DBP/SBP after the change in antihypertension treatment, followed by an exponential decrease in DBP/SBP characterized by a rate constant. Further details of the increase in blood pressure for subjects who were on antihypertensive drugs are provided in the supplementary material. The antihypertension intervention effect was estimated to cause an initial 6.54% (95% CI 5.71-7.36%) decrease in DBP/SBP, with the population mean half-life for dissipation of the effect estimated to be 5.3 h.
Coefficients of variation (CVs) for IIV were estimated to be 8.3% and 9.0%, respectively, for baseline DBP and SBP. The IIV for E max on k in was estimated to be 52.1% (95% CI 45.8-58.4%). Figure 1 shows the goodness-of-fit plots of PRED and IPRED vs. DBP and SBP; Figure 2 shows the VPC for the DBP and SBP E-R models.
E-R model for diarrhoea events
Base model. The base model for diarrhoea events was a logistic model for the ordered categorical variables (0 = none, 1 = mild, 2 = moderate, 3 = severe) and included Markovian elements to account for the high serial correlation between neighbouring observations. The inclusion of Markov elements introduced nine additional parameters and yielded a large drop in OFV (>155 000 points).
Drug effect model. The final drug effect model was an E max model for the predicted daily mean cediranib concentration (on the logit scale) and a linear time effect model (on the logit scale) to account for observations of higher grades of diarrhoea with longer treatment with cediranib within an individual patient.
Covariate model. None of the evaluated covariates (gender, age and body weight) were found to impact the ER model for diarrhoea events.
The results for the final diarrhoea model (Table 2) indicate that the probability of staying at the same grade as the previous day was very high; for example, the probability of not Figure 1 Observed vs. population-or individual-predicted DBP and SBP. DBP, diastolic blood pressure; IPRED, individual predictions; PRED, population predictions; SBP, systolic blood pressure having diarrhoea if no diarrhoea was observed on the previous day was over 99%. The largest difference between probabilities at baseline and at maximum drug effect was seen for the severe diarrhoea grade, whereby the probability of persisting diarrhoea was 86.6% and 99.5%, respectively. This indicates that severe diarrhoea was the most concentrationsensitive grade. Further details of the concentration-response relationship for diarrhoea are provided in the supplementary material. Figure 3 shows the VPC for modelling the diarrhoea event with the ordered categorical variable.
Discussion
E-R model for blood pressure
The final E-R model for DBP/SBP time courses included cosine functions to account for the circadian rhythm of DBP/SBP, in agreement with general observations of diurnal variations of DBP/SBP. Owing to the characteristics of the multiple studies pooled for this analysis, a different baseline for some of these studies and a diurnal cosine model with two amplitudes and two phases were used to model baseline DBP/SBP. Given that DBP and SBP were measured in pairs and showed good correlation, a simultaneous modelling of DBP and SBP was adopted, utilizing the L2 functionality in NONMEM to include within-sample correlation. This approach significantly reduced the NONMEM OFV and improved the goodness of fit to DBP/SBP time courses.
With the baseline DBP/SBP model fixed, the estimated drug effect was an E max model impacting the input rate constant of the indirect model for DBP/SBP, consistent with the mechanism of VEGFR-inhibitor-induced hypertension. Differences in the covariates sex, age, weight and medical history of hypertension were not estimated to be significant in impacting the drug-related model parameters E max and EC 50 . Estimated population mean E max was 20 and 26 mmHg for DBP and SBP, respectively, in line with observations in the raw data and similar to the observed maximum drug effect from administration of cediranib 45 or 60 mg. However, E max for blood pressure was associated with moderate IIV (52.1%). The model predicts a modest delay between the increase in DBP/SBP and cediranib concentrations in line with the estimated pharmacodynamic half-life of 2-3 h. However, the observed time to maximum increase in DBP/SBP was in the order of several days, which is, instead, in agreement with the pharmacokinetic half-life of cediranib (22 h). Thus, the time to maximum DBP/SBP effect was probably a result of cediranib accumulation rather than an effect delay. The final DBP/SBP model was used to predict typical DBP/SBP E-R curves (Figure 4) . The increase in either DBP or SBP was in the 10 mmHg range in the raw data, in agreement with model predictions, which were 7 mmHg (95% CI 3-13) and 8 mmHg (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , respectively, at the 20 mg dose level.
Patients receiving a change in their antihypertensive medication from baseline, were estimated to have an immediate mean reduction in blood pressure of 6.54% and a halflife of dissipation for the effect of 5.3 h. This suggests that an antihypertensive intervention effect on blood pressure will typically be dissipated in about 24 h (~4 half-lives). However, the analysis was only for data from the first antihypertensive intervention during the 6 weeks of cediranib treatment, and the complete effect of the intervention was probably not adequately characterized with such limited data.
E-R model for diarrhoea events
The diarrhoea model predicts an E-R curve heavily dependent on the previous day's observations, a consequence of the Markov elements, whereby a set of baseline probabilities and maximum effect were conditioned on previous observations. Diarrhoea can persist for several days when manifested, and the Markov element can account for the correlation between adjacent daily observations, allowing for differentiation of concentration-dependent effect from serial correlations. However, the serial correlations could be inflated by data imputations as a result of missing start and stop dates for different grades of diarrhoea.
With baseline diarrhoea events being characterized using a logistic model for ordered diarrhoea events, an E max model for average cediranib concentrations (on the logit scale) was identified as the final E-R model. The estimated EC 50 of the drug effect was within the predicted average exposure of the 20 mg dose. In addition, a time effect accounting for the increase in observed proportions of mild and higher grades of diarrhoea over time was supported by data. The increase over time in diarrhoea grades higher than mild was only seen in the observed data for cediranib doses of 30 mg and higher, while for cediranib 20 mg, the increase over time was mainly for mild diarrhoea. The time effect could be seen as a cumulative cediranib exposure effect on the gut. The covariates sex and body weight were not judged to be significant in impacting the drug-effect-related model parameters (E max and EC 50 ) in terms of substantial improvement in model fit, producing reliable model estimates or decreasing unexplained variability in drugrelated parameters.
Figure 4
Simulated typical exposure-response curves for diastolic and systolic blood pressure. Red areas are 95% confidence intervals of steady-state average cediranib concentrations following cediranib 20 mg once-daily dose administrations, purple areas are 95% prediction intervals of increase in DBP and SBP as a function of cediranib concentrations following cediranib 20 mg once-daily dose administrations
The estimated probability of having any grade of diarrhoea for a 20 mg dose was 0.58-3.8% per day; thus, for a typical individual, after 26-172 days of repeated-dose administration of cediranib 20 mg, the probability of having at least one episode of diarrhoea would be greater than 50%. The probability of severe diarrhoea resolving was estimated at 0.56-7.1% per day on a 20 mg dose at steady state, compared with 7.26-18.2% per day without exposure to cediranib, which would be reached after a few days of dosing interruptions. These grades have the largest changes between low and high concentrations ( Figure 5 ). Great uncertainty was predicted for the probability of diarrhoea grade changing from moderate to severe owing to the lack of real observations.
Conclusions
Maximum blood pressure increase was observed within the first few days of cediranib treatment, consistent with the pharmacokinetic profile of cediranib reaching steady state in about 5 days. The mean predicted increase in DBP and SBP for a 20 mg once-daily dose was 7 and 8 mmHg, respectively.
The probability of diarrhoea increased with cediranib concentration but was far more dependent on the status of diarrhoea predicted on the previous day. At the 20 mg dose, the probability of mild diarrhoea, but not the severity, increased over time. The model described a strong correlation between the probability of severe diarrhoea and average cediranib concentration. However, severe diarrhoea was predicted to be resolved rapidly after discontinuing cediranib treatment.
